Mineralys Therapeutics, INC 10-Q quarterly reports

Mineralys Therapeutics, Inc. (MLYS) reports a substantial increase in R&D expenses driven by a $200 million upfront payment for a license amendment, alongside securing a $100 million term loan and raising capital through equity offerings.

Mineralys Therapeutics reports Q1 2026 financial results, highlighting progress on its NDA for lorundrostat and a cash position of $646.1 million.

Mineralys Therapeutics reports strong clinical trial results for lorundrostat in hypertension and chronic kidney disease, bolstering its path to an NDA submission in late 2025 or early 2026.

Mineralys Therapeutics announced positive pivotal and Phase 2 clinical trial results for lorundrostat in hypertension and chronic kidney disease, while securing significant capital.

Mineralys Therapeutics announces positive results from pivotal trials for lorundrostat and reports its financial results for the first quarter of 2025, highlighting progress in clinical development and financial activities.

Mineralys Therapeutics reported a net loss of $56.3 million for the third quarter of 2024, while also providing updates on its ongoing clinical trials for lorundrostat.

Mineralys Therapeutics reported a net loss of $72.5 million for the first six months of 2024, while advancing its clinical trials for lorundrostat.

Mineralys Therapeutics reported a net loss of $31.5 million for the first quarter of 2024, while advancing its clinical programs for lorundrostat.